Tetra Bio-Pharma is taking a pharmaceutical pathway to discovering and developing cannabinoid-derived products, and Dr. Guy Chamberland explains to us how.
So basically, though Tetra is not a cannabis company, it has become inextricably linked to all things cannabis. They are not into growing, selling, cultivating, or promoting it. What they do is investigating hundreds of cannabinoid molecules to see what derivatives can be unleashed and turned into evidence-based medicines that address unmet medical needs.
Headquartered in Montréal, Canada Tetra Bio-Pharma, is already considered a global biopharmaceutical leader in cannabinoid-based drug discovery and development. The company is capturing the attention of investors and analysts and is becoming more visible by the day. All the investors and analysts see their accelerated regulatory achievements, clinical programs, and cost management as nothing less than remarkable. They even got their first smokable cannabinoid-derived product in the world approved by the regulatory investigation.
Other than GW Pharma, working with Health Canada and the Food and Drug Administration (FDA) on clinical trial programs with cannabinoid-derived products, Tetra Bio-Pharma is in the enviable position of being the only company in North America. The safety of pharmacokinetics, and pharmacodynamics of cannabinoid-based drugs targeted for the treatment of pain has also been proved significantly. Their products continue to advance through various phases of clinical development. Tetra Bio-Pharma is delivering on the need for rigorous scientific evidence. At the same time, it is building shareholder value with the introduction of cannabinoid-based natural health products that was well-planned to coincide with the legalization of recreational cannabis in Canada in October of 2018.